159 related articles for article (PubMed ID: 29107009)
1. Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets.
Poulin P; Arnett R
Regul Toxicol Pharmacol; 2017 Dec; 91():142-150. PubMed ID: 29107009
[TBL] [Abstract][Full Text] [Related]
2. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
[TBL] [Abstract][Full Text] [Related]
3. Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.
Bhat VS; Meek MEB; Valcke M; English C; Boobis A; Brown R
Crit Rev Toxicol; 2017 Oct; 47(9):729-749. PubMed ID: 28681680
[TBL] [Abstract][Full Text] [Related]
4. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
5. Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research.
Poulin P
J Pharm Sci; 2015 Jun; 104(6):2110-2118. PubMed ID: 25808270
[TBL] [Abstract][Full Text] [Related]
6. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
7. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Kirman CR; Sweeney LM; Corley R; Gargas ML
Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
[TBL] [Abstract][Full Text] [Related]
8. Albumin and Uptake of Drugs in Cells: Additional Validation Exercises of a Recently Published Equation that Quantifies the Albumin-Facilitated Uptake Mechanism(s) in Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling Research.
Poulin P; Haddad S
J Pharm Sci; 2015 Dec; 104(12):4448-4458. PubMed ID: 26457988
[TBL] [Abstract][Full Text] [Related]
9. Chemical-specific adjustment factors (inter-species toxicokinetics) to establish the ADI for steviol glycosides.
Roberts A; Lynch B; Rogerson R; Renwick A; Kern H; Coffee M; Cuellar-Kingston N; Eapen A; Crincoli C; Pugh G; Bhusari S; Purkayastha S; Carakostas M
Regul Toxicol Pharmacol; 2016 Aug; 79():91-102. PubMed ID: 27181453
[TBL] [Abstract][Full Text] [Related]
10. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel uncertainty factors and thresholds of toxicological concern for health hazard and risk assessment: Application to cleaning product ingredients.
Wang Z; Scott WC; Williams ES; Ciarlo M; DeLeo PC; Brooks BW
Environ Int; 2018 Apr; 113():357-376. PubMed ID: 29452931
[TBL] [Abstract][Full Text] [Related]
12. A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
Sussman RG; Naumann BD; Pfister T; Sehner C; Seaman C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S57-66. PubMed ID: 27221789
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of highly bound drugs: interspecies, intersubject, and related comparisons.
Collins JM; Klecker RW
J Clin Pharmacol; 2002 Sep; 42(9):971-5. PubMed ID: 12211222
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts.
Zu K; Pizzurro DM; Lewandowski TA; Goodman JE
Regul Toxicol Pharmacol; 2017 Oct; 89():83-94. PubMed ID: 28720346
[TBL] [Abstract][Full Text] [Related]
15. Uncertainty and variability in human exposure limits - a chemical-specific approach for ciprofloxacin and methotrexate.
Oldenkamp R; Huijbregts MA; Ragas AM
Crit Rev Toxicol; 2016; 46(3):261-78. PubMed ID: 26648512
[TBL] [Abstract][Full Text] [Related]
16. A chemical-specific adjustment factor for human interindividual differences in kinetics for glutamates (E620-625).
Rietjens IM; Tanaka T; Masuzawa Y; Nakamura H; Ishizaka Y; Teoh KN
Food Chem Toxicol; 2021 Jan; 147():111910. PubMed ID: 33309877
[TBL] [Abstract][Full Text] [Related]
17. Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?
Mukherjee SK; Ferry JB
Regul Toxicol Pharmacol; 2020 Aug; 115():104709. PubMed ID: 32553751
[TBL] [Abstract][Full Text] [Related]
18. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans.
Dorne JL; Renwick AG
Toxicol Sci; 2005 Jul; 86(1):20-6. PubMed ID: 15800035
[TBL] [Abstract][Full Text] [Related]
19. Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates.
Walton K; Dorne JL; Renwick AG
Food Chem Toxicol; 2001 Jul; 39(7):667-80. PubMed ID: 11397514
[TBL] [Abstract][Full Text] [Related]
20. Guidance on the establishment of acceptable daily exposure limits (ADE) to support Risk-Based Manufacture of Pharmaceutical Products.
Sargent EV; Faria E; Pfister T; Sussman RG
Regul Toxicol Pharmacol; 2013 Mar; 65(2):242-50. PubMed ID: 23291300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
